88089-94-5

Basic information

• Product Name: methyl 3-nitro-4-bromomethylbenzoate
• Synonyms: methyl 3-nitro-4-bromomethylbenzoate;Methyl 4-(bromomethyl)-3-nitrobenzoate
• CAS NO: 88089-94-5
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.06812
• Mol File: 88089-94-5.mol

Chemical Properties

• Boiling Point: 364.5±32.0 °C(Predicted)
• Appearance: /
• Density: 1.624±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: methyl 3-nitro-4-bromomethylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-nitro-4-bromomethylbenzoate(88089-94-5)
• EPA Substance Registry System: methyl 3-nitro-4-bromomethylbenzoate(88089-94-5)

Safety Data

• Hazardous Substances Data: 88089-94-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 3-nitro-4-bromomethylbenzoate is used as a reactant for the preparation of various complex organic molecules. Its presence allows for the creation of nitrobenzyl-substituted α-hydroxy esters, which are important in the synthesis of pharmaceuticals and other bioactive compounds.
Used in the Preparation of (Hydroxy)Oxindoles:
methyl 3-nitro-4-bromomethylbenzoate serves as a key intermediate in the synthesis of (hydroxy)oxindoles, which are structural motifs found in many natural products and biologically active molecules. The nitro and bromomethyl groups in methyl 3-nitro-4-bromomethylbenzoate facilitate the formation of these oxindole derivatives through a series of chemical reactions.
Used in the Synthesis of Benzosultams:
Methyl 3-nitro-4-bromomethylbenzoate is also utilized in the preparation of benzosultams, which are compounds with potential applications in medicinal chemistry. The synthesis of these compounds often involves the use of the bromomethyl group for subsequent reactions, such as nucleophilic substitution, to introduce various functional groups.

Upstream product

• 7356-11-8 4-methyl-3-nitro-benzoic acid methyl ester 
• 6232-88-8 4-bromomethylbenzoic Acid 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 67-56-1 methanol 
• 55715-03-2 4-bromomethyl-3-nitrobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 251941-63-6 4-[(7R,8R,9S,13S,14S,17S)-7-(11-Azido-undecyl)-13-methyl-17-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxymethyl]-3-nitro-benzoic acid methyl ester 
• 153813-69-5 methyl 4-formyl-3-nitrobenzoate 
• 220810-55-9 4-[(8R,9S,13S,14S,16S,17S)-16-(3-Azido-propyl)-13-methyl-17-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxymethyl]-3-nitro-benzoic acid methyl ester 
• 88071-93-6 nitro-3 phenoxymethyl-4 benzoate de methyle 
• 219763-69-6 2-((N-acetyl)aminomethyl)-5-((N-acetyl)carbamoyl)-1-nitrobenzene 
• 219763-70-9 2-((N-acetyl)aminomethyl)-5-((N-acetyl)carbamoyl)aniline 
• 199535-75-6 methyl 4-[(methylsulfonyl)methyl]-3-nitrobenzoate 

Relevant articles and documents

NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS

The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

SMALL MOLECULE MODULATORS OF HUMAN STING

The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING

The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)

PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS

In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.

NOVEL COMPOUNDS

The present invention relates substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds

A series of nitroaromatic compounds was synthesized and evaluated as potential antileishmanial and trypanocidal agents. Five compounds exerted significant anti-leishmanial activity in vitro against promastigotes forms of Leishmania (L.) amazonensis, with

INDAZOLE COMPOUNDS

This invention relates to indazole compounds of formula (I) or (II) shown below. Each variable in formula (I) or (II) is defined in the specification. These compounds can be used to treat cancer.

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

Methods of making 2,6-diaryl piperidine derivatives

Methods for preparing 2,6-diaryl piperidine derivatives are described. More particularly, 2,6-diaryl piperidines having formula 1-4 are prepared by cyclocondensation of an aryl or heteroaryl aldehyde with 1,3-acetonedicarboxylic acid.